Chemoprevention of severe neonatal hyperbilirubinemia

Semin Perinatol. 2004 Oct;28(5):365-8. doi: 10.1053/j.semperi.2004.09.004.

Abstract

The uses of synthetic heme analogues that are competitive inhibitors of heme oxygenase, the rate-limiting enzyme in the production of bilirubin, represent a novel means of controlling severe hyperbilirubinemia in the newborn. The logic of this approach and the use of stannsoporfin (tin mesoporphyrin) as the compound of choice are discussed.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.
  • Research Support, U.S. Gov't, P.H.S.
  • Review

MeSH terms

  • Enzyme Inhibitors / therapeutic use*
  • Heme Oxygenase (Decyclizing) / antagonists & inhibitors*
  • Humans
  • Infant, Newborn
  • Jaundice, Neonatal / prevention & control*
  • Metalloporphyrins / therapeutic use*

Substances

  • Enzyme Inhibitors
  • Metalloporphyrins
  • tin mesoporphyrin
  • Heme Oxygenase (Decyclizing)